Their findings showed that in patients with CLL, the medication ibrutinib was found to significantly increase the number of CD4+ and CD8+ T cells, particularly in the effector/effector memory subsets. This evidence concerns the gene CD4 and B-cell chronic lymphocytic leukemia.